News

Published on 19 Oct 2023 on Simply Wall St. via Yahoo Finance

Akerna Corp.'s (NASDAQ:KERN) Price Is Right But Growth Is Lacking


Article preview image

Akerna Corp.'s (NASDAQ:KERN) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right now compared to the Software industry in the United States, where around half of the companies have P/S ratios above 4.2x and even P/S above 10x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.

View our latest analysis for Akerna

ps-multiple-vs-industry

NASDAQ.KERN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Akerna Corp.'s (NASDAQ:KERN) Price Is Right But Growth Is Lacking

Akerna Corp.'s (NASDAQ:KERN) price-to-sales (or "P/S") ratio of 0.2x might make it look like a st...

Simply Wall St. via Yahoo Finance 19 Oct 2023

All You Need to Know About Akerna Corp. (KERN) Rating Upgrade to Buy

Akerna Corp. (KERN) could be a solid choice for investors given its recent upgrade to a Zacks Ran...

Zacks via Yahoo Finance 6 Jun 2023

Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes

Cardiovascular Systems CSII suffered operating loss amid several macroeconomic hurdles. The stock...

Zacks via Yahoo Finance 20 Mar 2023

Here's Why You Should Retain Boston Scientific (BSX) Now

Boston Scientific Corporation BSX is well poised for growth in coming quarters, backed by impress...

Zacks via Yahoo Finance 20 Mar 2023

Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2

Tandem Diabetes Care, Inc.TNDM recently announced favorable results from the Pediatric Artificial...

Zacks via Yahoo Finance 17 Mar 2023

NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth

NuVasive's NUVA impending merger with Globus Medical GMED seems strategically aligned with the co...

Zacks via Yahoo Finance 17 Mar 2023

Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes

Abbott ABT is gaining from new product launches and strategic acquisitions. However, due to macro...

Zacks via Yahoo Finance 17 Mar 2023

Reasons Why You Should Retain ResMed (RMD) Stock For Now

ResMed Inc. RMD is gaining from continued demand for its sleep and respiratory care devices. The ...

Zacks via Yahoo Finance 16 Mar 2023

Syneos Health's (SYNH) Product Launch Aids, FX Woe Hurts

Syneos Health SYNH has been gaining from partnerships and a strong Clinical Solutions segment. Ho...

Zacks via Yahoo Finance 15 Mar 2023

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

Laboratory Corporation of America Holdings, or LabCorp LH, is gaining from strength in its Drug D...

Zacks via Yahoo Finance 14 Mar 2023